These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 37531032)

  • 101. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
    Lipton RB; Halker Singh RB; Mechtler L; McVige J; Ma J; Yu SY; Stokes J; Dabruzzo B; Gandhi P; Ashina M
    Cephalalgia; 2023 Aug; 51(8):3331024231190296. PubMed ID: 37638400
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Safety evaluation of oral calcitonin-gene-related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis.
    Lee S; Staatz CE; Han N; Baek IH
    Eur J Clin Pharmacol; 2022 Sep; 78(9):1365-1376. PubMed ID: 35729340
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling.
    Woodhead JL; Siler SQ; Howell BA; Watkins PB; Conway C
    Toxicol Sci; 2022 Jun; 188(1):108-116. PubMed ID: 35556143
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.
    Thaliffdeen R; Yu A; Rascati K
    Clin Drug Investig; 2024 Mar; 44(3):209-217. PubMed ID: 38381352
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions.
    Al-Hassany L; Goadsby PJ; Danser AHJ; MaassenVanDenBrink A
    Lancet Neurol; 2022 Mar; 21(3):284-294. PubMed ID: 35093196
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Role of CGRP in Migraine.
    Edvinsson L
    Handb Exp Pharmacol; 2019; 255():121-130. PubMed ID: 30725283
    [TBL] [Abstract][Full Text] [Related]  

  • 107. What's New in the Treatment of Migraine?
    Digre KB
    J Neuroophthalmol; 2019 Sep; 39(3):352-359. PubMed ID: 31393282
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Acute Treatment of Migraine: What has Changed in Pharmacotherapies?
    Yang CP; Huang KT; Chang CM; Yang CC; Wang SJ
    Neurol India; 2021; 69(Supplement):S25-S42. PubMed ID: 34003146
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Novel FDA-approved zavegepant drug for treating migraine.
    Ahmed U; Saleem MM; Osman MA; Shamat SF
    Ann Med Surg (Lond); 2024 Feb; 86(2):923-925. PubMed ID: 38333255
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
    Lipton RB; Croop R; Stock EG; Stock DA; Morris BA; Frost M; Dubowchik GM; Conway CM; Coric V; Goadsby PJ
    N Engl J Med; 2019 Jul; 381(2):142-149. PubMed ID: 31291516
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment.
    Edvinsson L; Warfvinge K
    Cephalalgia; 2019 Mar; 39(3):366-373. PubMed ID: 29020807
    [TBL] [Abstract][Full Text] [Related]  

  • 112. CGRP and migraine: from bench to bedside.
    Edvinsson L
    Rev Neurol (Paris); 2021 Sep; 177(7):785-790. PubMed ID: 34275653
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study.
    Alsaadi T; Suliman R; Santos V; Al Qaisi I; Carmina P; Aldaher B; Haddad S; Bader Y
    Neurol Ther; 2024 Apr; 13(2):465-473. PubMed ID: 38361080
    [TBL] [Abstract][Full Text] [Related]  

  • 114. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.
    Boinpally R; McNamee B; Yao L; Butler M; McGeeney D; Borbridge L; Periclou A
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1099-1107. PubMed ID: 33942560
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine.
    Lupi C; Benemei S; Guerzoni S; Pellesi L; Negro A
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):189-198. PubMed ID: 30714429
    [TBL] [Abstract][Full Text] [Related]  

  • 116. The Headache Pipeline: Excitement and Uncertainty.
    Rapoport AM; McAllister P
    Headache; 2020 Jan; 60(1):190-199. PubMed ID: 31889312
    [TBL] [Abstract][Full Text] [Related]  

  • 117. CGRP inhibitors for migraine prophylaxis: a safety review.
    Rivera-Mancilla E; Villalón CM; MaassenVanDenBrink A
    Expert Opin Drug Saf; 2020 Oct; 19(10):1237-1250. PubMed ID: 32811190
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
    Nedd M; Garland S; Falk N; Wilk A
    Ann Pharmacother; 2022 Mar; 56(3):346-351. PubMed ID: 34109839
    [TBL] [Abstract][Full Text] [Related]  

  • 119. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
    Voss T; Lipton RB; Dodick DW; Dupre N; Ge JY; Bachman R; Assaid C; Aurora SK; Michelson D
    Cephalalgia; 2016 Aug; 36(9):887-98. PubMed ID: 27269043
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.
    Gérard AO; Merino D; Van Obberghen EK; Rocher F; Destere A; Lantéri-Minet M; Drici MD
    J Headache Pain; 2022 May; 23(1):53. PubMed ID: 35505285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.